Safety and how the body handles ABBV-243 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, randomized, placebo-controlled, single-ascending-dose study gives healthy adult volunteers single intravenous (IV) or single subcutaneous (SC) doses of ABBV-243 (Part 1) and a single IV dose in healthy Asian adults (Part 2) to characterize safety, tolerability, pharmacokinetics, and immunogenicity. Participants are enrolled in escalating dose cohorts with some receiving placebo and will attend scheduled clinic visits for medical assessments, blood draws, and questionnaires. The protocol collects time‑course blood samples to measure drug levels, monitors for immune responses against the drug, and records any adverse events. Results will be used to define safe dose ranges and inform dosing and route choices for later patient trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals between 18 and 60 years of age inclusive at the time of Screening.
* BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* Females, Non-Childbearing Potential are eligible as defined by meeting the following criteria:

  * Permanent sterility due to a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  * Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; investigator discretion should be applied to determining study entry.
  * Postmenopausal female who is age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level ≥ 30 IU/L.
  * Postmenopausal female who is age \> 55 years with no menses for 12 or more months without an alternative medical cause.
* Females, Childbearing Potential are defined as all other females who do not meet the above criteria and must adhere to the following:

  * Must not be pregnant or breastfeeding.
  * Must agree to avoid pregnancy while taking study treatment(s) and for at least 200 days after the last dose of study treatment.
  * Must agree to use a contraceptive method listed below (as per local regulations) that is highly effective (with a failure rate of \< 1% per year, when used consistently and correctly). Participants must provide documentation to the site.
  * Bilateral tubal occlusion/ligation.
  * Intrauterine device (IUD) to be inserted at least 30 days prior to Screening.
  * Intrauterine hormone-releasing system (IUS) to be inserted at least 30 days prior to Screening.
* Part 2 only:

Healthy Japanese and Han Chinese male or female; between 18 and 60 years of age, inclusive at the time of Screening.

\- Han Chinese participants must be first- or second-generation Han Chinese of full Chinese parentage. First-generation participants are defined as those born in China to two parents and four grandparents also born in China of full Chinese descent. Second-generation participants are defined as those born outside of China to two parents and four grandparents born in China of full Chinese descent.

OR

\- Japanese participants must be first- or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation subjects born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.

Exclusion Criteria:

* History: of epilepsy, any clinically significant cardiovascular, respiratory (except mild asthma as a child), renal, endocrine, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
* History of any clinically significant sensitivity or allergy to any medication or food.
* Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma, or localized carcinoma in situ of the cervix.
* History or evidence of active Tuberculosis (TB) disease or latent TB infection.

Where it's running

• Acpru /Id# 279789
  Grayslake, Illinois, United States Recruiting

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of Exercise Snacks on Muscle Size and Strength in Healthy Young Adults

  This study tests whether many small workouts throughout the week can build muscle size and improve strength in healthy, untrained young adults compared with the usual twice-weekly workouts.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT07760597

• ORX489 safety and dosing in healthy adults ages 18 to 60

  This will test whether ORX489 tablets are safe, well tolerated, and how they are processed in the body in healthy men and women aged 18 to 60.

  Recruiting Phase 1 Centessa Pharmaceuticals (UK) Limited · Lincoln, Nebraska · NCT07413666

• ReHIIT Prehabilitation in Healthy Adults

  This pilot tests a combined resistance and high‑intensity interval training program to establish baseline physiology in healthy adults before applying findings to cancer patients.

  Recruiting University of Nottingham · Derby, Derbyshire · NCT07313332

• Safety and drug levels of a 3‑month naltrexone implant (BICX104) with or without bupropion versus monthly Vivitrol injections

  This will test whether a three‑month naltrexone implant (BICX104), given alone or with extended‑release bupropion, is safe and keeps steady drug levels compared with monthly Vivitrol injections in healthy adults.

  Recruiting Phase 1 BioCorRx Pharmaceuticals Inc · Miami, Florida · NCT07269873

• Compare two forms and doses of vonafexor and see if the high dose interacts with other drugs

  This test looks at how two doses and two formulations of vonafexor (EYP651 and vonafexor acid) are absorbed and processed in healthy adults and whether the high dose interacts with common medicines.

  Recruiting Phase 1 Enyo Pharma · Gières · NCT07251153

• Low-frequency vibrating mat for sleep and daily stress recovery

  This test will see if using a low-frequency vibrating mat at home for three weeks improves stress recovery, sleep quality, mood, and attention in healthy adults aged 18-45.

  Recruiting Florida International University · Miami, Florida · NCT07221318

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.